After much effort has been made over years, an SSTR2 subtype-selective agonist paltusotine has recently been developed by Crinetics, which is an orally bioavailable non-peptide small molecule and is undergoing phase 3 trials for the clinical treatment of acromegaly and other NETs. Here, SSTR2 is linked to acromegaly.